ABL2
ABL2 (Tyrosine-protein kinase ABL2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Endometrial cancer, Lung cancer and 2 more.
Overview
Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signalling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin-bundling activity.
CIViC holds 1 clinical evidence item and 0 assertions across 3 variants, naming Imatinib and Dasatinib. Open Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes literature 0.89, animal model 0.26, genetic association 0.33, somatic mutation 0.83). IntOGen calls it a driver in 2 cohorts (2 activating, 0 loss-of-function), covering Invasive Breast Carcinoma, Endometrial Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ABL2 (Tyrosine-protein kinase ABL2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Endometrial cancer, Lung cancer and 2 more.
- 1 · What it is
ABL2 (Tyrosine-protein kinase ABL2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Endometrial cancer, Lung cancer and 2 more.
- 2 · What goes wrong in cancer
Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis.
- 3 · How drugs use it
No product in this corpus aims at ABL2 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:77 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P42684 (protein name, function text, keywords and locations (REST API)); CIViC gene ABL2 (1 evidence items, 0 assertions, 3 variants; diseases: Lung Adenocarcinoma (GraphQL API, CC0)); Open Targets ENSG00000143322 (association with cancer (MONDO_0004992) 0.68; per-cancer scores at or above 0.5: skin cancer 0.52, breast cancer 0.57, lung cancer 0.53 (GraphQL API, CC0)); IntOGen ABL2 (driver in 2 cohorts (Act 2, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signalling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin-bundling activity. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as CRK, CRKL, DOK1 or ARHGAP35. Adhesion-dependent phosphorylation of ARHGAP35 promotes its association with RASA1, resulting in recruitment of ARHGAP35 to the cell periphery where it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases like PDGFRB and other substrates which are involved in endocytosis regulation such as RIN1. Location: Cytoplasm, cytoskeleton (UniProt). Locus 1q25.2 (HGNC).
- Breast cancer: Open Targets association 0.57 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA)
- Endometrial cancer: IntOGen driver in 1 cohort (UCEC)
- Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903)
- Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898)
- Non-small-cell lung cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; IntOGen calls it an activating (Act) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ABL2" OR ABSTRACT:"ABL2" OR TITLE:"ABL proto-oncogene 2, non-receptor tyrosine kinase" OR ABSTRACT:"ABL proto-oncogene 2, non-receptor tyrosine kinase" OR TITLE:"Tyrosine-protein kinase ABL2" OR ABSTRACT:"Tyrosine-protein kinase ABL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ABL2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetEBF1
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetFUBP1
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetMECOM
Shares Lung cancer (all types), Skin cancer (all types), Endometrial cancer, Breast cancer (all types).
- TargetLZTR1
Shares Lung cancer (all types), Skin cancer (all types), Endometrial cancer, Breast cancer (all types).
- TargetCRLF2
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetBARD1
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetNUP98
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.